BillionToOne prices upsized IPO at $60 per share

BillionToOne Inc. (NASDAQ: BLLN) priced its upsized initial public offering of 4,551,100 shares of Class A common stock at $60.00 per share, the molecular diagnostics company announced.

The company granted underwriters a 30-day option to purchase up to 682,665 additional shares at the offering price, minus underwriting discounts and commissions. Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, under ticker symbol "BLLN."

The offering is expected to generate gross proceeds of approximately $273.1 million before deducting underwriting discounts, commissions and other offering expenses. The figure excludes proceeds from the underwriters' option to purchase additional shares. The offering is scheduled to close on November 7, 2025, subject to customary closing conditions.

J.P. Morgan, Piper Sandler, Jefferies and William Blair serve as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG also act as book-running managers.

BillionToOne, headquartered in Menlo Park, California, develops molecular diagnostic tests. The company's platform uses what it describes as Quantitative Counting Templates technology for DNA molecule counting at the single-molecule level.

The Securities and Exchange Commission declared effective a registration statement on Form S-1 related to the securities. The offering is being conducted solely through a prospectus, according to the company's statement.

You May Also Be Interested In